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invasive cardiac testing to assess the likelihood of obstructive coronary artery dis-
ease (CAD). We hypothesized that use of a gene expression score (GES) would reduce 
diagnostic costs among non-acute symptomatic patients presenting to cardiolo-
gists. Methods: The IMPACT-CARD Trial (NCT01251302) prospectively enrolled 88 
patients without known CAD who presented with chest pain and related symptoms 
and were referred to one of six cardiologists. The cardiologist’s diagnostic strategy 
was evaluated before and after GES testing, and diagnostic testing in a matched 
historical cohort of 83 patients was extracted from medical records. The GES is a 
previously validated, blood-based diagnostic test that determines the likelihood 
of obstructive CAD, with a negative predictive value of 96% among low GES (≤ 15) 
patients. We estimated per-procedure costs from commercially insured patients in 
a large, national health claims database. We applied these costs to the tests per-
formed in the matched historical cohort and recommended in the prospective arm 
post-GES to calculate the cost of diagnostic evaluation in the trial. Given the rule-out 
nature of the GES, we focused this economic analysis on low GES patients. Results: 
There were 52 low GES study patients. The total cost of cardiac diagnostic testing 
in these patients was lower than in the 52 matched controls ($2,450 versus $1,735 
per patient, inclusive of the GES cost, p= 0.23), though the difference was not sta-
tistically significant. This finding represents 29% savings ($715 per patient) in car-
diac testing costs. No differences in clinical outcomes were observed between the 
groups. ConClusions: Physician use of the GES may be associated with reductions 
in diagnostic testing costs in low score patients. These savings reflect the potential 
economic utility of the GES in the diagnosis of obstructive CAD.
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objeCtives: Transcatheter Aortic Valve Implantation (TAVI) is a cost-effective life-
saving therapy for patients suffering from severe aortic stenosis (SAS) who are 
unable to undergo, or face prohibitively high risk to survival from, conventional 
open-heart surgery. The therapy is available in Canada on a limited basis, and access 
lags that in other developed nations. Access issues will become more acute in com-
ing years as the population further ages, though to-date no efforts have been made 
to quantify need for TAVI procedures and the potentially unavoidable deaths occur-
ring each year from capacity shortfalls. Methods: We developed a population-
based stock-and-flow simulation model using Microsoft EXCEL to quantify the 
prevalence and incidence of SAS, capacity to perform TAVI procedure, SAS patients 
longevity with and without TAVI and avoidable deaths from lack of access under 
various capacity-building scenarios for the provinces of Ontario, Quebec, British 
Columbia and Alberta. Our model was populated with data from published peer-
reviewed articles, the StatsCan CANSIM database and the support of the Cardiac 
Care Network. Results: We estimate that there is a severe shortage of capacity to 
perform TAVI procedures in relation to population needs that will result in 2,882 
avoidable deaths over the three years from 2014 to 2017. The gap between need 
and capacity is greatest in Ontario. ConClusions: An increase in the capacity to 
perform TAVI procedures is needed to reduce the number of access-related mortality 
in Ontario, Quebec, British Columbia and Alberta.
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objeCtives: Syncope is a common medical event that accounts for 1-3% of all visits 
to the emergency departments (ED), hospitalizations and falls, and is associated with 
high morbidity and deterioration of quality-of-life. Conventional testing strategies fail 
to diagnose underlying causes in more than 1/3 of cases, leading to repeat episodes 
and costly health care system interactions. We sought to better understand the bur-
den of unexplained syncope on four Provincial health care systems in Canada and 
evaluate the impact of adopting testing strategies centered on Insertable Cardiac 
Monitors (ICM) as an alternative to current practice. Methods: We evaluated the eco-
nomic burden and implications of alternative strategies for the provinces of Ontario, 
Quebec, British Columbia and Alberta using a multi-cohort Markov-based simulation 
model developed in Microsoft Excel. Our model was populated with data from peer-
reviewed papers, CIHI Patient Cost Estimator, the StatsCan CANSIM database and phy-
sician schedules of fees. Results: We estimate that between 2014 and 2023, syncope 
will affect 223,000 people each year across the four provinces, and account for 97,000 
ED visits, 11,000 hospitalizations and 6,000 falls annually in this period. A total of 1.5 
million diagnostic tests will be performed under conventional strategies, compared 
to 626 thousand tests if every syncope patient post-2014 were assigned ICM following 
an initial unsuccessful diagnosis (43% reduction). The ICM strategy would also elimi-
nate 12% of blackouts, 9% of falls, and 21% of ED visits and hospitalizations related 
to Syncopal events. The proportion of patients diagnosed would increase from 15% 
to 47% at 36 months, and the strategy would be largely cost-neutral with an average 
annual reduction of $43M per year in Syncope-related expenditures. ConClusions: 
We find that the burden of unexplained Syncope on Canadian health care systems is 
substantial, and wider utilization of ICMs in diagnosis could reduce this burden while 
improving the patient experience.
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objeCtives: This study aims to stimulate the use of secondary data in health eco-
nomic analyses, based on a better understanding of available possibilities using 
Brazilian public health databases (DATASUS) and to develop a case study focused on 
the treatment of patients with acute myocardial infarction (AMI). Methods: This 
study was conceived as a transversal observation of the available public databases, 
including outpatient and inpatient information. Conducting studies using real 
world data is possible due to the identification of the individual under treatment. 
This identification does not allow determining the patient’s identity, but allows 
tracking patients’ treatment and outcomes. The total amounts of spending in the 
outpatient and inpatient settings have been analyzed. Besides, a case study was 
developed focusing on patients hospitalized due to AMI. The quantity of treatments 
performed, treatment centers involved and the associated mortality were evaluated. 
High volume centers (HVCs) were compared to low volume centers (LVCs). Results: 
In the outpatient setting, about 3 million patients were treated in 2011 resulting in 
expenses of approximately 8.7 billion dollars. In the inpatient setting, more than 9 
million patients’ records were found, resulting in expenditures of around 13.1 billion 
dollars. In 2012, 57,133 hospitalizations due to AMI were identified in 2,138 centers. 
Eighty per cent of the hospitalizations occurred in 25% of the centers. In the HVCs 
an average of 87 hospitalizations due to AMI were recorded per year versus 7 in the 
LVCs. The mortality rate due to AMI was lower in the HVCs when compared to the 
LVCs (14.9% vs 15.8%; p< 0.05) and the average length of stay was higher (8.7 vs 5.2 
days). ConClusions: Health managers should use the thorough analyzes based 
on secondary data provided by DATASUS for decision making and to better allocate 
scarce resources in health care.
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objeCtives: Medication reconciliation is a necessary process for the delivery of 
optimal patient care, yet can be difficult to do in the primary care setting due to 
limited time and resources. Dramatic improvements in health information technol-
ogy may facilitate accurate and real-time medication reconciliation. The purpose of 
this study is to determine the potential impact of linked pharmacy claims within to 
the primary care electronic health record (EHR) to inform medication reconciliation 
in primary care practice. Methods: We conducted a retrospective cohort study in 
patients that were prescribed a new antihypertensive between January 2011 and 
September 2012. We compared patients’ active medications as recorded in a primary 
care practice EHR with those that were listed in pharmacy claims data available 
through the EHR. Only medications that were active in the 120 days prior to the new 
antihypertensive were considered. Medications that appeared in one data source 
but not the other were categorized as discrepancies. The primary outcome was the 
presence of at least one discrepancy. Predictors of discrepancy risk were calculated 
through logistic regression. Results: A total of 609 patients qualified for study. 
Amongst all patients, 2947 medications were reconciled, with 1401 as discrepancies. 
The majority of patients (468, 76.9%) had at least one discrepancy. Predictors of the 
risk of having discrepancies included total medication count (OR: 0.17, p= < 0.0001), 
at least one non-cardiovascular related comorbidity (OR: 0.84 p= 0.0001) and a hos-
pitalization in the previous year (OR: 0.48, p= 0.007). ConClusions: A high rate of 
medication discrepancies was found amongst patients, along with significant pre-
dictors of occurrence. The use of linked pharmacy claims was able to show a more 
complete picture of a patient’s medication use patterns. Such automated solutions 
could be used to screen available data sources to uncover discrepancies and identify 
patients who may benefit from tailored clinical interventions.
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objeCtives: Pharmaceutical companies adopt distinctive marketing strategies to 
advertise drugs for hypertension and psychosis. This study explored the variance 
in stereotypes related to gender disparity and activity status (passive and active) 
used in video direct-to-consumer advertisements for anti-psychotics and statins 
class of drugs. Methods: Fifty-eight unique video DTCA aired on NBC and CNN 
evening news were analyzed. The Vanderbilt TV News Archive Database was utilized 
to obtain random samples from each year which constituted to final sample of nine 
anti-psychotic and forty-nine statins ads aired between 1st January 1998 and 31st 
December 2011. Inter-rater reliability was assessed using Cohen’s Kappa and was 
found to be acceptable for the variables used in the instrument. Data was analyzed 
using Fischer Exact test using SAS 9.3®. Results: Out of the 58 ads, 41-ads por-
trayed males and 32-ads portrayed females as the primary character. The propor-
tion of male character was significantly higher in statins ads compared to ads for 
antipsychotics (79.59 % vs. 22.22 %, p= 0.0016). However, the proportion of female 
character was significantly greater in ads for antipsychotics compared to statins 
(88.89 % vs. 48.98%, p= 0.034). In addition, a female character with passive status was 
significantly higher in antipsychotic ads compared to statins (66.67 % vs. 32.65 %, 
p= 0.055). In contrast, a male character with active status was significantly greater 
in statins compared to antipsychotics (38.78 % vs. 0 %, p= 0.0012). ConClusions: 
Gender and activity status stereotypes are quite prevalent in both anti-depressants 
and cardiovascular drugs. Males with active status were more likely to be featured 
in statins whereas female characters with passive status were more likely to be 
featured in anti-psychotics. Stereotypes in DTCA may potentially bias the decision 
making ability and prescribing behavior of physicians.
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